The responses revealed underestimation to the importance of risk assessment in the intermediate risk chemotherapy-induced neutropenia and subsequent over prescription of G-CSF in the same group which is inconsistent with the guideline recommendations. This evidence concerns the gene CSF3 and Decreased total neutrophil count.